April 10th, 2025 | 07:30 CEST
A buying opportunity in the price horror? Novo Nordisk, BioNTech, and Defence Therapeutics!
For Novo Nordisk shareholders, who have been spoiled by price gains, the current nightmare shows no sign of ending. The notion that pharmaceutical stocks are a safe haven in turbulent times is only partially true at the moment. Novo Nordisk shares are trading at their lowest level since 2022. A buying opportunity? Yes, analysts believe, but the Trump-induced chaos is not going away anytime soon. For those looking to invest in relative strength, there is currently no getting around Defence Therapeutics. The biotech company is not affected by tariff disputes and is taking big steps towards monetization. Yesterday, there was a strong price jump. Is a takeover coming soon? For example, BioNTech has full coffers and, as the latest IPO shows, is keen to invest in companies in the oncology sector.
time to read: 3 minutes
|
Author:
Fabian Lorenz
ISIN:
NOVO NORDISK A/S | DK0062498333 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , DEFENCE THERAPEUTICS INC | CA24463V1013
Table of contents:
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
Defence Therapeutics: More than 20% gain yesterday
Defence Therapeutics shareholders do not seem to be affected by the tariff panic and general uncertainty. The Canadian biotech company's shares continue to trade well above their level at the beginning of the year. And the prospects look good for the rally to continue. On the one hand, the Company is still in the research phase, focusing on advanced cancer therapeutics and delivery technologies. This gives it the flexibility to choose the best location for future production – if it is not taken over first, which would also speak in favor of a rising share. In addition, the Company is making great strides in development and has its sights firmly set on monetization. The out-licensing of its platform is expected to contribute to this.
Yesterday, the latest announcement caused the share price to jump to over EUR 0.60. This enabled the Company to win a new partner. Canadian Nuclear Laboratories ("CNL"), Canada's leading nuclear research facility, will conduct preclinical studies combining alpha-particle radiotherapy Actinium-225 (Ac-225) with Defence's proprietary Accum® delivery technology.
Ac-225 has already shown great promise as a targeted radiation therapy for cancer. Ac-225 emits powerful alpha particles that cause irreparable damage to the DNA of cancer cells, leading to cell death. The collaboration with CNL aims to test various antibodies modified with the Accum® technology to find the best variant to penetrate the cell nucleus. This could reduce the required dosage of Ac-225, thus minimizing the side effects without compromising therapeutic efficacy.
Defence CEO Sébastien Plouffe commented: "We believe that Accum® will significantly enhance the efficacy of Ac-225 immunoconjugates by improving therapeutic potency and tumor targeting. Our technology's ability to facilitate escape from the endosome and increase the presence of therapeutics in cell nuclei enhances the effectiveness of the alpha particles at their primary target. The synergy between Accum® and CNL's expertise will advance precision oncology and lead to more effective and safer treatments."
The market potential is huge. According to straitsresearch.com, the global radiopharmaceuticals market is expected to reach USD 16.87 billion by 2033. Defence Therapeutics wants a slice of this cake.
Novo Nordisk: Nightmare as a price opportunity?
Unlike Defence Therapeutics, the nightmare for shareholders of Novo Nordisk, who have been accustomed to price gains, shows no sign of ending. Yesterday, the shares of the Danish pharmaceutical giant fell by more than 5% and are trading below the EUR 55 mark. The shares have not been this low since 2022.
Recently, US President Donald Trump once again emphasized at an event that the pharmaceutical industry is facing massive tariffs. However, according to an analyst from BMO, shifting production to the US hardly presents an alternative for the pharmaceutical industry. This is because the supply chains in the industry are considered too complex, as reported by the news agency dpa-AFX.
On Monday, Deutsche Bank confirmed its "Buy" recommendation for Novo Nordisk shares but reduced its price target from DKK 900 to DKK 750.
BioNTech: Partner before IPO
It is currently quiet around the BioNTech pipeline. What is new is that BioNTech is getting involved in the IPO of Duality Biologics (DualityBio). The Chinese biotechnology company is currently going public in Hong Kong. The aim is to raise up to HKD 1.56 billion to advance the development of innovative antibody-drug conjugates (ADCs) – a novel class of cancer drugs. The IPO comes at a time of geopolitical uncertainty, marked by trade conflicts between China and the US.
A key strategic partner of DualityBio is BioNTech. The German biotech company is not only one of DualityBio's core investors but also holds licensing rights to several of DualityBio's drug candidates. It also provides support through its development network and regulatory expertise. In total, BioNTech and other investors have already committed around USD 65 million – about a third of the IPO target – which strengthens the success of the IPO despite the uncertain economic situation.
DualityBio is focusing on two core products. DB-1303, a HER2-targeted ADC that is positioned as a direct competitor to Enhertu (from AstraZeneca and Daiichi Sankyo). BioNTech supports the development and holds the global rights to the compound.
DB-1311 is an ADC that targets tumor antigen B7-H3. It is currently in Phase 1/2a trials for solid tumors, and BioNTech also holds the licensing rights. However, there are issues: Three lawsuits are pending in China involving patent infringements of DualityBio's molecular structure technology platforms. However, the Company rejects these claims as unfounded.
Defence Therapeutics still appears undervalued and continues its upward trend with positive news. In addition, the takeover fantasy grows with each advance. Novo Nordisk may seem cheap, but how and when the tariff nightmare will be resolved remains entirely uncertain. BioNTech is also suffering from tariff issues but should attract attention over the course of the year with news from its development pipeline.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
